Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Sep 15;382(Pt 3):1031-8.
doi: 10.1042/BJ20040729.

Highly sensitive intramolecularly quenched fluorogenic substrates for renin based on the combination of L-2-amino-3-(7-methoxy-4-coumaryl)propionic acid with 2,4-dinitrophenyl groups at various positions

Affiliations

Highly sensitive intramolecularly quenched fluorogenic substrates for renin based on the combination of L-2-amino-3-(7-methoxy-4-coumaryl)propionic acid with 2,4-dinitrophenyl groups at various positions

Katherine Paschalidou et al. Biochem J. .

Abstract

The development of renin inhibitors for the treatment of hypertension requires highly sensitive substrates to evaluate potency and to characterize the mechanism of tight-binding inhibitors. A series of intramolecularly quenched fluorogenic renin substrates, based on the N-terminal tetradecapeptide sequence of human angiotensinogen (hTDP), was synthesized using a solid-phase technique. Incorporation of the fluorescent amino acid L-Amp [L-2-amino-3-(7-methoxy-4-coumaryl)propionic acid] and the DNP (2,4-dinitrophenyl) group at various positions resulted in >90% quenching efficiency and strong product fluorescence. Shortening the hTDP sequence to an octapeptide from histidine in P5 to histidine in P3' (substrate 3) resulted in an acceptable k(cat)/K(m) (41000 M(-1).s(-1)) and further systematic variation gave substrate 9, DNP-Lys-His-Pro-Phe-His-Leu-Val-Ile-His-L-Amp, with a k(cat)/K(m) value of 350000 M(-1).s(-1) and 94% quenching efficiency. The free side chain of lysine, replacing the isoleucine residue at P6 position in the angiotensinogen sequence, contributed to the increased value for k(cat). The pH dependence of k(cat)/K(m) for renin and substrate 9 showed that the optimal pH is at pH 6-7. It also showed two titrating groups on the acidic side of the pH optimum, and one titrating group with a pK(a) of 7.8 on the alkaline side. The combination of good kinetic and spectroscopic properties resulted in a >20-fold improvement in the sensitivity of renin assay, compared with the commercial substrate Arg-Glu(EDANS)-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(DABCYL)-Arg [where EDANS is 5-[(2-aminoethyl)amino]naphthalene-1-sulphonic acid and DABCYL is 4-(4-dimethylaminophenylazo)benzoic acid] (k(cat)/K(m)=268000 M(-1) x s(-1), quenching efficiency <80%). The detection limit in a microplate renin assay was 60 pM, making substrate 9 well suited for the evaluation of inhibitors at picomolar concentrations.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Determination of Michaelis–Menten parameters for the renin-catalysed hydrolysis of substrate 9 by the initial-rate method
The initial-rate assay was performed at the following conditions: renin concentration, 0.27 nM; five substrate concentrations over the Km range 0.5–3; assay buffer, 50 mM Mops/NaOH, pH 7.0, 2 mM EDTA, 0.5% BSA, 0.1% NaN3 and 1% DMSO; excitation/emission wavelengths 328/388 nm; and temperature, 37 °C. Product concentration was determined by HPLC. Data were fitted to the Michaelis–Menten equation.
Figure 2
Figure 2. Renin-catalysed hydrolysis of substrate 9 (▪) and substrate 20 (○)
Progress curves under pseudo-first-order conditions: renin concentration, 8.2 nM; substrate concentration 0.2 μM; assay buffer, 50 mM Mops/NaOH, pH 7.0, 2 mM EDTA, 0.5% BSA, 0.1% NaN3 and 1% DMSO; excitation/emission wavelengths, 328/388 nm for substrate 9 and 340/485 nm for substrate 20; and temperature, 37 °C. The inset shows hydrolysis of substrate 20 using a 7-fold-increased sensitivity of the spectrofluorimeter.
Figure 3
Figure 3. Determination of renin activity using substrates 9 (▪) and 20 (○) in a 96-well microplate
Conditions: renin concentration, 0.03–2 nM; substrate concentration, 5 μM; assay buffer, 50 mM Mops/NaOH, pH 7.0, 2 mM EDTA, 0.5% BSA, 0.1% NaN3 and 1% DMSO; excitation/emission wavelengths, 328/388 nm for substrate 9 and 340/485 nm for substrate 20; and temperature, 37 °C. Assay time was 10 min at 37 °C, the plate was read at 30 s intervals and slopes were calculated. Results are means±S.D. for three wells. RFU, relative fluorescence units.
Figure 4
Figure 4. pH-dependence of kcat/Km of renin-catalysed hydrolysis of substrate 9
Buffers (50 mM) containing 0.5% BSA, 2 mM EDTA and 0.1% NaN3 were prepared from sodium acetate (pH 4.5, 4.9 and 5.4), Mes (pH 5.5, 5.8 and 6.2), Mops (pH 6.7, 7.1, 7.7 and 8.1) and Taps (8.2, 8.7, 9.1 and 9.6) using correction factors for the change of pKa values with temperature. The final renin concentration was 8.2–41 nM. Values for kcat/Km were determined by the progress-curve method at 0.2 μM substrate concentrations and fitted to eqns (5) (continuous line) and (6) (dotted line). Results from two experiments are shown.

Similar articles

Cited by

References

    1. He F. J., MacGregor G. A. Salt, blood pressure and the renin–angiotensin system. J. Renin Angiotensin Aldosterone Syst. 2003;4:11–16. - PubMed
    1. De Gasparo M., Catt K. J., Inagami T., Wright J. W., Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000;52:415–472. - PubMed
    1. Kaschina E., Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Pressure. 2003;12:70–88. - PubMed
    1. Waeber B., Nussberger J., Brunner H. R. Angiotensin-converting enzyme inhibitors in hypertension. In: Laragh J. H., Brenner B. M., editors. Hypertension: Pathophysiology, Diagnosis and Management. 2nd edn. New York: Raven Press; 1995. pp. 2861–2876.
    1. Taal M. W., Brenner B. M. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000;57:1803–1817. - PubMed

Publication types